Healthy Volunteers Study
Part of paid clinical trials in Philadelphia, Pennsylvania.
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Study ID
- NCT06962059
- Status
- Recruiting
Conditions
- Genetic Predisposition to Disease
- Ovarian Cancer
Eligibility Criteria
- Sex
- FEMALE
- Age
- 30 Years - 50 Years
- Healthy Volunteers
- Accepted
Interventions
- Self-Administered Sample Collection — OTHERParticipants will collect vaginal swabs and a stool sample.
Study Details
The purpose of this study is to examine the role of the bacterial environments and metabolites in the early detection and prediction of ovarian cancer development. Vaginal swabs and stool samples will be collected from healthy volunteers, or those without a known ovarian cancer diagnosis or genetic ovarian cancer risk. These samples will be compared to samples from participants with increased cancer risk and ovarian cancer diagnoses.
Key Dates
- Start date
- Apr 21, 2025
- Status verified
- Feb 2026
- Primary completion
- Jan 15, 2027
- Completion
- May 25, 2027
Study Design
- Enrollment
- 50 participants (estimated)
Arms
- Arm: Healthy VolunteerFemales 30 or older who do not have a genetic predisposition to ovarian cancer, are unaffected by cancer, and have not had bilateral oophorectomy.
Primary Outcome Measure
Microbiome Involvement [ Time Frame: One-time sample donation of vaginal swabs collected at the time of the patient's appointment. A subsequent stool sample will be provided within a week of the vaginal swab. ]
Central Contacts
- Catherine Wolfe, BA215-360-0422
- Jamie Brower, MS215-662-7245
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Abramson Cancer Center of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | Susan Domchek, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Philadelphia, PA
By condition
By specialty
Related Studies
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of PreventionRecruiting · University Medical Center Nijmegen · Chicago, Illinois
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · Irvine, California
- A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or UbamatamabPHASE1/PHASE2 · Recruiting · Regeneron Pharmaceuticals · Duarte, California